Clinical trialObservationalUnknown
Acquisition of Portal Venous CTCs and Exosomes From Patients With Pancreatic Cancer by EUS
Acquisition of Portal Venous Circulating Tumor Cells and Exosomes From Patients With Pancreatic Cancer by Endoscopic Ultrasound: a Prospective Study
- Outcome
- Outcome unknown
- Phase
- Observational
- Status
- Unknown
- Study type
- Observational
- Start
- 1 August 2018
- Listed end
- September 2020
- Enrollment
- 30 participants
- Sites
- 1
- Primary outcomes
- The difference of the amount of circulating tumor cells acquisited from portal venous blood between patients with pancreatic cancer and benign pancreatic diseases; The difference of the exosomes acquisited from portal venous blood between patients with pancreatic cancer and benign pancreatic diseases
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 31 January 2019
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The investigators are going to explore the diagnostic and prognostic value of circulating tumor cells and exosomes extracted from the portal venous blood obtained with endoscopic ultrasound in pancreatic cancer patients.
Detailed description public domain (ClinicalTrials.gov)
As the prognosis of pancreatic cancer, a kind of malignant tumor, remains poor due to the low diagnostic rate at the early stage, there is still a significant clinical need to determine individualized tumor molecular profiles and personalized risk for recurrence. Circulating tumor cells (CTCs) and exosomes from patients with primary tumors may hold promise in serving as an informative biomarker to address this clinical need. Here in this study, the investigators are going to explore the feasibility and safety of sampling portal venous blood via endoscopic ultrasound (EUS), and detect portal venous CTCs and analyze mRNA markers of exosomes by RNA-seq. The investigators aim to explore the potential molecular mechanisms in tumor microenvironment and mechanisms of drug resistance.